



UNITED STATES PATENT AND TRADEMARK OFFICE


COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/085,233	02/28/2002	Maria Alexandra Glucksman	MP101-021P1RNM

Jean M. Silveri
Millennium Pharmaceuticals, Inc.
75 Sidney Street
Cambridge, MA 02139



CONFIRMATION NO. 6932
FORMALITIES LETTER



OC000000008567084

Date Mailed: 08/02/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



0.350

Practitioner's Docket No. MPI01-021P1RNM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Maria Alexandra Glucksmann
Application No.: 10/085,233 Group No.: 1645
Filed: February 28, 2002 Examiner: N/A
For: 93870, A HUMAN G-PROTEIN COUPLED RECEPTOR AND USES THEREFOR

Box Sequence
Commissioner for Patents
P.O. Box 2327
Arlington, VA 22202

**SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,
AND/OR AMENDMENT PERTAINING THERETO
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE**

1. [x] This replies to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated August 2, 2002.
- [x] A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures is enclosed.

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, Jean M. Silveri
(type or print name of person signing below)

state the following:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Box Sequence, P.O. Box 2327, Arlington, VA 22202.
37 C.F.R. SECTION 1.8(a) 37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Address" Mailing Label No. _____

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Simonne Corriveau
Simonne Corriveau

(type or print name of person certifying)

Date: September 30, 2002

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

ITEMS BEING SUBMITTED

3. Submitted herewith is/are:

- A. ☒ 7 pages of "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B. ☐ An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C. ☒ A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D. ☐ Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:

Application No.:

Filed:

For:

Group No.:

Examiner:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form

(other application)

"Sequence Identifier"

(this application)

- E. ☒ A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. Section 1.821(g).
- ☐ Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. Section 1.821(b).

Practitioner's Docket No. MPI01-021P1RNM

F. ☒ Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.

☐ Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

**STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

A. ☒ Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.

B. ☒ All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

EXTENSION OF TERM

5. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.

(a) ☐ Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:

<u>Extension (months)</u>	<u>Fee for other than small entity</u>	<u>Fee for small entity</u>
<input type="checkbox"/> one month	\$ 110.00	\$ 55.00
<input type="checkbox"/> two months	\$ 390.00	\$ 195.00
<input type="checkbox"/> three months	\$ 890.00	\$ 445.00
<input type="checkbox"/> four months	\$1,390.00	\$ 695.00

Fee \$0.00

If an additional extension of time is required, please consider this a petition therefor.

☐ An extension for _____ months has already been secured, and the fee paid therefor of \$0.00 is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$0.00

Practitioner's Docket No. MPI01-021P1RNM

OR

- (b) ☒ Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

FEE PAYMENT

6. ☐ Attached is a check in the sum of \$ _____ .
- ☐ Charge Account No. 501668 the sum of \$0.00 .
A duplicate of this transmittal is attached.


FEE DEFICIENCY

8. ☒ If any additional extension and/or fee is required, charge Account No. 501668 .

September 30, 2002

MILLENNIUM PHARMACEUTICALS, INC.

By



Jean M. Silveri

Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820

0570
06/9

BIOTECHNICAL
SYSTEMS
BRANCH

**RAW SEQUENCE LISTING
ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/085,233 A
Source: OIPE
Date Processed by STIC: 6/17/02

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



OIPE

Does Not Comply
Corrected Diskette Needed See pg. 7

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/085,233A

DATE: 06/17/2002

TIME: 14:46:04

for explanation of
errors

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\06172002\J085233A.raw

3 <110> APPLICANT: YISSUM Research Development Company of the Hewbrew University of Jerusalem

5 <120> TITLE OF INVENTION: Fce-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES, A

6 METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

8 <130> FILE REFERENCE: 1268-067

C--> 10 <140> CURRENT APPLICATION NUMBER: US/10/085,233A

C--> 11 <141> CURRENT FILING DATE: 2002-06-10

13 <150> PRIOR APPLICATION NUMBER: IL 116436

14 <151> PRIOR FILING DATE: 1995-12-18

16 <150> PRIOR APPLICATION NUMBER: PCT / IL96 / 00181

17 <151> PRIOR FILING DATE: 1996-12-18

19 <160> NUMBER OF SEQ ID NOS: 8

21 <170> SOFTWARE: PatentIn version 3.0

23 <210> SEQ ID NO: 1

24 <211> LENGTH: 1512

25 <212> TYPE: DNA

C--> 26 <213> ORGANISM: Artificial

28 <220> FEATURE:

29 <223> OTHER INFORMATION: Description of Artificial Sequence: Fce2-3-PE40

31 <220> FEATURE:

32 <221> NAME/KEY: CDS

33 <222> LOCATION: (1)..(1512)

35 <400> SEQUENCE: 1

```

36 atg gag cag caa tgg atg tct gaa agc acc ttc acc tgc aag gtc acc      48
37 Met Glu Gln Gln Trp Met Ser Glu Ser Thr Phe Thr Cys Lys Val Thr
38 1                    5                    10                    15
40 tcc caa ggc gta gac tat ttg gcc cac act cgg aga tgc cca gat cat      96
41 Ser Gln Gly Val Asp Tyr Leu Ala His Thr Arg Arg Cys Pro Asp His
42                20                25                30
44 gag cca gcc ggt gtg att acc tac ctg atc cca ccc agc ccc ctg gac      144
45 Glu Pro Ala Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp
46                35                40                45
48 ctg tat caa aac ggt gct ccc aag ctt acc tgt ctg gtg gtg gac ctg      192
49 Leu Tyr Gln Asn Gly Ala Pro Lys Leu Thr Cys Leu Val Val Asp Leu
50    50                55                60
52 gaa agc gag aag aat gtc aat gtg acg tgg aac caa gag aag aag act      240
53 Glu Ser Glu Lys Asn Val Asn Val Thr Trp Asn Gln Glu Lys Lys Thr
54 65                70                75                80
56 tca gtc tca gca tcc cag tgg tac act aag cac cac aat aac gcc aca      288
57 Ser Val Ser Ala Ser Gln Trp Tyr Thr Lys His His Asn Asn Ala Thr
58                85                90                95
60 act agt atc acc tcc atc ctg cct gta gtt gcc aag gac tgg att gaa      336
61 Thr Ser Ile Thr Ser Ile Leu Pro Val Val Ala Lys Asp Trp Ile Glu

```

62

100

105

110

RAW SEQUENCE LISTING

DATE: 06/17/2002

PATENT APPLICATION: US/10/085,233A

TIME: 14:46:04

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\06172002\J085233A.raw

```

64 ggc tac ggc tat cag tgc ata gtg gac cac cct gat ttt ccc aag ccc      384
65 Gly Tyr Gly Tyr Gln Cys Ile Val Asp His Pro Asp Phe Pro Lys Pro
66      115      120      125
68 att gtg cgt tcc atc acc aag acc cca cat atg gcc gaa gag ggc ggc      432
69 Ile Val Arg Ser Ile Thr Lys Thr Pro His Met Ala Glu Glu Gly Gly
70      130      135      140
72 agc ctg gcc gcg ctg acc gcg cac cag gct tgc cac ctg ccg ctg gag      480
73 Ser Leu Ala Ala Leu Thr Ala His Gln Ala Cys His Leu Pro Leu Glu
74 145      150      155      160
76 act ttc acc cgt cat cgc cag ccg cgc gcc tgg gaa caa ctg gag cag      528
77 Thr Phe Thr Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu Glu Gln
78      165      170      175
80 tgc ggc tat ccg gtg cag cgg ctg gtc gcc ctc tac ctg gcg gcg cgg      576
81 Cys Gly Tyr Pro Val Gln Arg Leu Val Ala Leu Tyr Leu Ala Ala Arg
82      180      185      190
84 ctg tcg tgg aac cag gtc gac cag gtg atc cgc aac gcc ctg gcc agc      624
85 Leu Ser Trp Asn Gln Val Asp Gln Val Ile Arg Asn Ala Leu Ala Ser
86      195      200      205
88 ccc gcc agc gcc gcc gac ctg gcc gaa gcg atc cgc gag cag ccg gag      672
89 Pro Gly Ser Gly Gly Asp Leu Gly Glu Ala Ile Arg Glu Gln Pro Glu
90      210      215      220
92 cag gcc cgt ctg gcc ctg acc ctg gcc gcc gcc gag agc gag cgc ttc      720
93 Gln Ala Arg Leu Ala Leu Thr Leu Ala Ala Ala Glu Ser Glu Arg Phe
94 225      230      235      240
96 gtc cgg cag gcc acc gcc aac gac gag gcc gcc gcc gcc aac gcc gac      768
97 Val Arg Gln Gly Thr Gly Asn Asp Glu Ala Gly Ala Ala Asn Ala Asp
98      245      250      255
100 gtg gtg agc ctg acc tgc ccg gtc gcc gcc ggt gaa tgc gcg gcc ccg      816
101 Val Val Ser Leu Thr Cys Pro Val Ala Ala Gly Glu Cys Ala Gly Pro
102      260      265      270
104 gcg gac agc gcc gac gcc ctg ctg gag cgc aac tat ccc act gcc gcg      864
105 Ala Asp Ser Gly Asp Ala Leu Leu Glu Arg Asn Tyr Pro Thr Gly Ala
106      275      280      285
108 gag ttc ctc gcc gac gcc gcc gac gtc agc ttc agc acc cgc gcc acg      912
109 Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser Thr Arg Gly Thr
110      290      295      300
112 cag aac tgg acg gtg gag cgg ctg ctc cag gcg cac cgc caa ctg gag      960
113 Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala His Arg Gln Leu Glu
114 305      310      315      320
116 gag cgc gcc tat gtg ttc gtc gcc tac cac gcc acc ttc ctc gaa gcg      1008
117 Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala
118      325      330      335
120 gcg caa agc atc gtc ttc gcc ggg gtg cgc gcg cgc agc cag gac ctc      1056
121 Ala Gln Ser Ile Val Phe Gly Gly Val Arg Ala Arg Ser Gln Asp Leu
122      340      345      350
124 gac gcg atc tgg cgc ggt ttc tat atc gcc gcc gat ccg gcg ctg gcc      1104
125 Asp Ala Ile Trp Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala
126      355      360      365
128 tac gcc tac gcc cag gac cag gaa ccc gac gca cgc gcc cgg atc cgc      1152

```

RAW SEQUENCE LISTING

DATE: 06/17/2002

PATENT APPLICATION: US/10/085,233A

TIME: 14:46:04

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\06172002\J085233A.raw

```

129 Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala Arg Gly Arg Ile Arg
130      370                      375                      380
132 aac ggt gcc ctg ctg cgg gtc tat gtc ccg cgc tcg agc ctg ccg ggc      1200
133 Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser Leu Pro Gly
134 385                      390                      395                      400
136 ttc tac cgc acc agc ctg acc ctg gcc gcg ccg gag gcg gcg ggc gag      1248
137 Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu Ala Ala Gly Glu
138                      405                      410                      415
140 gtc gaa cgg ctg atc ggc cat ccg ctg ccg ctg cgc ctg gac gcc atc      1296
141 Val Glu Arg Leu Ile Gly His Pro Leu Pro Leu Arg Leu Asp Ala Ile
142                      420                      425                      430
144 acc ggc ccc gag gag gaa ggc ggg cgc ctg gag acc att ctc ggc tgg      1344
145 Thr Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp
146      435                      440                      445
148 ccg ctg gcc gag cgc acc gtg gtg att ccc tcg gcg atc ccc acc gac      1392
149 Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser Ala Ile Pro Thr Asp
150      450                      455                      460
152 ccg cgc aac gtc ggc ggc gac ctc gac ccg tcc agc atc ccc gac aag      1440
153 Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser Ser Ile Pro Asp Lys
154 465                      470                      475                      480
156 gaa cag gcg atc agc gcc ctg ccg gac tac gcc agc cag ccc ggc aaa      1488
157 Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser Gln Pro Gly Lys
158                      485                      490                      495
160 ccg ccg cgc gag gac ctg aag taa      1512
161 Pro Pro Arg Glu Asp Leu Lys
162      500

```

165 <210> SEQ ID NO: 2

166 <211> LENGTH: 503

167 <212> TYPE: PRT

C--> 168 <213> ORGANISM: Artificial

W--> 170 <220> FEATURE:

W--> 170 <223> OTHER INFORMATION:

170 <400> SEQUENCE: 2

```

172 Met Glu Gln Gln Trp Met Ser Glu Ser Thr Phe Thr Cys Lys Val Thr
173 1                      5                      10                      15
176 Ser Gln Gly Val Asp Tyr Leu Ala His Thr Arg Arg Cys Pro Asp His
177      20                      25                      30
180 Glu Pro Ala Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp
181      35                      40                      45
184 Leu Tyr Gln Asn Gly Ala Pro Lys Leu Thr Cys Leu Val Val Asp Leu
185      50                      55                      60
188 Glu Ser Glu Lys Asn Val Asn Val Thr Trp Asn Gln Glu Lys Lys Thr
189 65                      70                      75                      80
192 Ser Val Ser Ala Ser Gln Trp Tyr Thr Lys His His Asn Asn Ala Thr
193      85                      90                      95
196 Thr Ser Ile Thr Ser Ile Leu Pro Val Val Ala Lys Asp Trp Ile Glu
197      100                     105                     110
200 Gly Tyr Gly Tyr Gln Cys Ile Val Asp His Pro Asp Phe Pro Lys Pro
201      115                     120                     125

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/085,233A

DATE: 06/17/2002

TIME: 14:46:04

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\06172002\J085233A.raw

204 Ile Val Arg Ser Ile Thr Lys Thr Pro His Met Ala Glu Glu Gly Gly
 205 130 135 140
 208 Ser Leu Ala Ala Leu Thr Ala His Gln Ala Cys His Leu Pro Leu Glu
 209 145 150 155 160
 212 Thr Phe Thr Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu Glu Gln
 213 165 170 175
 216 Cys Gly Tyr Pro Val Gln Arg Leu Val Ala Leu Tyr Leu Ala Ala Arg
 217 180 185 190
 220 Leu Ser Trp Asn Gln Val Asp Gln Val Ile Arg Asn Ala Leu Ala Ser
 221 195 200 205
 224 Pro Gly Ser Gly Gly Asp Leu Gly Glu Ala Ile Arg Glu Gln Pro Glu
 225 210 215 220
 228 Gln Ala Arg Leu Ala Leu Thr Leu Ala Ala Glu Ser Glu Arg Phe
 229 225 230 235 240
 232 Val Arg Gln Gly Thr Gly Asn Asp Glu Ala Gly Ala Ala Asn Ala Asp
 233 245 250 255
 236 Val Val Ser Leu Thr Cys Pro Val Ala Ala Gly Glu Cys Ala Gly Pro
 237 260 265 270
 240 Ala Asp Ser Gly Asp Ala Leu Leu Glu Arg Asn Tyr Pro Thr Gly Ala
 241 275 280 285
 244 Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser Thr Arg Gly Thr
 245 290 295 300
 248 Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala His Arg Gln Leu Glu
 249 305 310 315 320
 252 Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala
 253 325 330 335
 256 Ala Gln Ser Ile Val Phe Gly Gly Val Arg Ala Arg Ser Gln Asp Leu
 257 340 345 350
 260 Asp Ala Ile Trp Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala
 261 355 360 365
 264 Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala Arg Gly Arg Ile Arg
 265 370 375 380
 268 Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser Leu Pro Gly
 269 385 390 395 400
 272 Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu Ala Ala Gly Glu
 273 405 410 415
 276 Val Glu Arg Leu Ile Gly His Pro Leu Pro Leu Arg Leu Asp Ala Ile
 277 420 425 430
 280 Thr Gly Pro Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp
 281 435 440 445
 284 Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser Ala Ile Pro Thr Asp
 285 450 455 460
 288 Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser Ile Pro Asp Lys
 289 465 470 475 480
 292 Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser Gln Pro Gly Lys
 293 485 490 495
 296 Pro Pro Arg Glu Asp Leu Lys
 297 500
 300 <210> SEQ ID NO: 3

RAW SEQUENCE LISTING

DATE: 06/17/2002

PATENT APPLICATION: US/10/085,233A

TIME: 14:46:04

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\06172002\J085233A.raw

```

301 <211> LENGTH: 2031
302 <212> TYPE: DNA
C--> 303 <213> ORGANISM: Artificial
305 <220> FEATURE:
306 <223> OTHER INFORMATION: Description of Artificial Sequence: Fce2-4-PE40
308 <220> FEATURE:
309 <221> NAME/KEY: CDS
310 <222> LOCATION: (1)..(2031)
312 <400> SEQUENCE: 3
313 atg cga cct gtc aac atc act gag ccc acc ttg gag cta ctc cat tca      48
314 Met Arg Pro Val Asn Ile Thr Glu Pro Thr Leu Glu Leu Leu His Ser
315 1      5      10      15
317 tcc tgc gac ccc aat gca ttc cac tcc acc atc cag ctg tac tgc ttc      96
318 Ser Cys Asp Pro Asn Ala Phe His Ser Thr Ile Gln Leu Tyr Cys Phe
319      20      25      30
321 att tat ggc cac atc cta aat gat gtc tct gtc agc tgg cta atg gac      144
322 Ile Tyr Gly His Ile Leu Asn Asp Val Ser Val Ser Trp Leu Met Asp
323      35      40      45
325 gat cgg gag ata act gat aca ctt gca caa act gtt cta atc aag gag      192
326 Asp Arg Glu Ile Thr Asp Thr Leu Ala Gln Thr Val Leu Ile Lys Glu
327      50      55      60
329 gaa ggc aaa cta gcc tct acc tgc agt aaa ctc aac atc act gag cag      240
330 Glu Gly Lys Leu Ala Ser Thr Cys Ser Lys Leu Asn Ile Thr Glu Gln
331 65      70      75      80
333 caa tgg atg tct gaa agc acc ttc acc tgc aag gtc acc tcc caa ggc      288
334 Gln Trp Met Ser Glu Ser Thr Phe Thr Cys Lys Val Thr Ser Gln Gly
335      85      90      95
337 gta gac tat ttg gcc cac act cgg aga tgc cca gat cat gag cca cgg      336
338 Val Asp Tyr Leu Ala His Thr Arg Arg Cys Pro Asp His Glu Pro Arg
339      100      105      110
341 ggt gtg att acc tac ctg atc cca ccc agc ccc ctg gac ctg tat caa      384
342 Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp Leu Tyr Gln
343      115      120      125
345 aac ggt gct ccc aag ctt acc tgt ctg gtg gtg gac ctg gaa agc gag      432
346 Asn Gly Ala Pro Lys Leu Thr Cys Leu Val Val Asp Leu Glu Ser Glu
347      130      135      140
349 aag aat gtc aat gtg acg tgg aac caa gag aag aag act tca gtc tca      480
350 Lys Asn Val Asn Val Thr Trp Asn Gln Glu Lys Lys Thr Ser Val Ser
351 145      150      155      160
353 gca tcc cag tgg tac act aag cac cac aat aac ggc aca act agt atc      528
354 Ala Ser Gln Trp Tyr Thr Lys His His Asn Asn Gly Thr Thr Ser Ile
355      165      170      175
357 acc tcc atc ctg cct gta gtt gcc aag gac tgg att gaa ggc tac ggc      576
358 Thr Ser Ile Leu Pro Val Val Ala Lys Asp Trp Ile Glu Gly Tyr Gly
359      180      185      190
361 tat cag tgc ata gtg gac cac cct gat ttt ccc aag ccc att gtg cgt      624
362 Tyr Gln Cys Ile Val Asp His Pro Asp Phe Pro Lys Pro Ile Val Arg
363      195      200      205
365 tcc atc acc aag acc cca ggc cag cgc tca gcc ccc gag gta tat gtg      672

```

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 06/17/2002
PATENT APPLICATION: US/10/085,233A TIME: 14:46:05

Input Set : A:\pto.vsk.txt
Output Set: N:\CRF3\06172002\J085233A.raw

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 3

Invalid <213> Response:

Use of "Artificial" only as "<213> Organism" response is incomplete,
per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

Seq#:1,2,3,4

Use of <220> Feature(NEW RULES):

Sequence(s) are missing the <220> Feature and associated headings.
Use of <220> to <223> is MANDATORY if <213> ORGANISM is "Artificial Sequence"
or "Unknown". Please explain source of genetic material in <220> to <223>
section (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp.29631-32)
(Sec.1.823 of new Rules)

Seq#:2,4

VERIFICATION SUMMARY

DATE: 06/17/2002

PATENT APPLICATION: US/10/085,233A

TIME: 14:46:05

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\06172002\J085233A.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application Number
L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:26 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:1
L:168 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:2
L:170 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:170 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:303 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:3
L:489 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:4
L:491 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:491 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION: